Shares of Artelo Biosciences edged up after the company said preclinical data for its ART12.11 drug candidate showed cognitive benefits over existing antidepressants. The stock rose 63% to $16.35 ...

Roughly one in ten Americans suffers from major depressive disorder (MDD) at any given time. In total, up to 20 percent of ...

The magic mushroom compound psilocybin shows long-lasting antidepressant effects in a clinical trial, with patients reporting ...

Differentiated Therapeutic Profile: These findings underscore ART12.11’s potential as a highly differentiated candidate for treating depression and anxiety, especially in patients where cognitive ...

Compared with placebo, pramipexole added to antidepressants reduces symptoms significantly at 12 weeks in treatment-resistant depression, a trial finds.

Saffron shows promise as a natural treatment for depression and cognitive decline, performing as well as standard drugs in ...

Antidepressants are widely used as a drug based intervention to treat more severe cases of postnatal depression. While they ...

A drug commonly used for Parkinson’s disease, called pramipexole, has shown strong results in helping people with depression that hasn’t improved with standard treatments. This new finding comes from ...

Depression and anxiety can happen to anyone at any time in their life. As we get older, changes in our health, losing loved ...